X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PIRAMAL ENTERPRISES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PIRAMAL ENTERPRISES CIPLA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 44.6 36.6 121.9% View Chart
P/BV x 3.8 3.0 125.7% View Chart
Dividend Yield % 0.3 0.8 42.0%  

Financials

 CIPLA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    CIPLA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
CIPLA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6222,095 29.7%   
Low Rs4581,025 44.7%   
Sales per share (Unadj.) Rs181.9492.8 36.9%  
Earnings per share (Unadj.) Rs12.972.6 17.7%  
Cash flow per share (Unadj.) Rs29.394.7 31.0%  
Dividends per share (Unadj.) Rs2.0021.00 9.5%  
Dividend yield (eoy) %0.41.3 27.5%  
Book value per share (Unadj.) Rs155.7862.5 18.1%  
Shares outstanding (eoy) m804.51172.56 466.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.2 93.8%   
Avg P/E ratio x42.021.5 195.2%  
P/CF ratio (eoy) x18.416.5 111.8%  
Price / Book Value ratio x3.51.8 191.8%  
Dividend payout %15.528.9 53.7%   
Avg Mkt Cap Rs m434,516269,194 161.4%   
No. of employees `00023.04.0 574.2%   
Total wages/salary Rs m26,33817,939 146.8%   
Avg. sales/employee Rs Th6,349.121,190.3 30.0%   
Avg. wages/employee Rs Th1,143.04,470.1 25.6%   
Avg. net profit/employee Rs Th449.33,120.0 14.4%   
INCOME DATA
Net Sales Rs m146,30285,037 172.0%  
Other income Rs m2,2872,338 97.8%   
Total revenues Rs m148,58987,374 170.1%   
Gross profit Rs m24,75834,991 70.8%  
Depreciation Rs m13,2293,817 346.6%   
Interest Rs m1,59420,310 7.8%   
Profit before tax Rs m12,22213,202 92.6%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m1,7982,281 78.8%   
Profit after tax Rs m10,35412,520 82.7%  
Gross profit margin %16.941.1 41.1%  
Effective tax rate %14.717.3 85.1%   
Net profit margin %7.114.7 48.1%  
BALANCE SHEET DATA
Current assets Rs m87,37087,590 99.7%   
Current liabilities Rs m33,081185,578 17.8%   
Net working cap to sales %37.1-115.2 -32.2%  
Current ratio x2.60.5 559.6%  
Inventory Days Days8731 280.2%  
Debtors Days Days6248 131.0%  
Net fixed assets Rs m111,567108,523 102.8%   
Share capital Rs m1,609345 466.2%   
"Free" reserves Rs m123,645148,481 83.3%   
Net worth Rs m125,254148,826 84.2%   
Long term debt Rs m36,454144,957 25.1%   
Total assets Rs m209,532482,394 43.4%  
Interest coverage x8.71.7 525.3%   
Debt to equity ratio x0.31.0 29.9%  
Sales to assets ratio x0.70.2 396.1%   
Return on assets %5.76.8 83.8%  
Return on equity %8.38.4 98.3%  
Return on capital %8.512.0 71.1%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06615,001 340.4%   
Fx outflow Rs m17,6785,150 343.3%   
Net fx Rs m33,3889,851 338.9%   
CASH FLOW
From Operations Rs m23,824-100,393 -23.7%  
From Investments Rs m-13,127-24,202 54.2%  
From Financial Activity Rs m-13,239135,705 -9.8%  
Net Cashflow Rs m-2,47811,110 -22.3%  

Share Holding

Indian Promoters % 16.0 52.9 30.2%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.0 305.0%  
FIIs % 23.7 26.6 89.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 16.5 158.8%  
Shareholders   161,166 93,274 172.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare CIPLA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS